AQR Capital Management LLC Decreases Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

AQR Capital Management LLC trimmed its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 43.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,522,154 shares of the company's stock after selling 1,188,452 shares during the quarter. AQR Capital Management LLC owned approximately 1.21% of Organogenesis worth $4,871,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northern Trust Corp raised its stake in Organogenesis by 2.9% in the 4th quarter. Northern Trust Corp now owns 616,089 shares of the company's stock valued at $1,971,000 after purchasing an additional 17,196 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Organogenesis during the fourth quarter worth about $206,000. Aquatic Capital Management LLC acquired a new position in shares of Organogenesis in the fourth quarter valued at approximately $111,000. MetLife Investment Management LLC lifted its stake in shares of Organogenesis by 34.9% during the fourth quarter. MetLife Investment Management LLC now owns 36,593 shares of the company's stock valued at $117,000 after buying an additional 9,465 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Organogenesis by 18.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after acquiring an additional 442,772 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley increased their price target on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th.

Organogenesis Trading Down 42.9 %

Shares of NASDAQ ORGO traded down $2.29 on Friday, reaching $3.05. 11,223,439 shares of the company traded hands, compared to its average volume of 1,162,301. The company has a 50 day moving average of $4.65 and a 200 day moving average of $3.90. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $6.71. The stock has a market capitalization of $386.90 million, a PE ratio of -50.83 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). The company had revenue of $86.69 million during the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. On average, equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Insider Activity

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the transaction, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 36.90% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.